US$130m China-NZ CAR-T deal lands in Auckland as Guangdong cell therapy tech achieves first commercial

Summary

Wellington Zhaotai Therapies Limited (WZTL), the holding platform of China's Zhaotai, has signed a CAR-T cell therapy technology sublicence agreement with New Zealand's BioOra in Auckland, with a total contract value of US$130 million. It marks the first time a Guangdong-developed tumour immunology cell therapy product has been successfully licensed for commercialisation to a developed country. WZTL is 86.5 percent owned by China's Zhaotai and 13.5 percent by MBL, an entity under New Zealand's Malaghan Institute of Medical Research.

Under the agreement, the CAR-T therapy products will be jointly advanced through subsequent clinical development and commercialisation in agreed international markets outside Greater China and India. Tang Chaoyang, chairman of China's Zhaotai and WZTL, said the US$130m transaction is the result of nearly a decade of sustained investment by the Chinese and New Zealand research teams: China's Zhaotai began technical cooperation with the Malaghan Institute in 2016, the two parties jointly established WZTL in 2017, launched New Zealand's first nationwide CAR-T clinical trial in 2019, and in 2023 the project was highlighted by then New Zealand Ambassador to China Grahame Morton at the Guangzhou event marking the 50th anniversary of China-New Zealand diplomatic relations. Previously, Zhaotai licensed its lymphoma CAR-T innovative drug for commercialisation to India's Dr Reddy's Laboratories in 2022, and in 2024 China Customs approved its CAR-T cell products for entry into Hong Kong hospitals.

Tang said the signing represents a leap from 'product going global' to 'technology going global', and that the parties will continue to work with BioOra and more industry chain partners to complete subsequent clinical development and commercialisation of the therapy in agreed international markets.

Commentary

The US$130m CAR-T technology sublicence agreement between China's Zhaotai and New Zealand's BioOra is a key step in China-New Zealand biomedical cooperation, moving from clinical research to commercialisation. As a frontier direction in tumour immunotherapy, CAR-T has a global market expected to exceed US$10 billion by 2028, but high costs and manufacturing complexity have limited its uptake. In this cooperation, Zhaotai provides proprietary technology while the New Zealand side contributes clinical resources and an international commercialisation network, creating complementarity.

For NZ SMEs, this is not just a single transaction but could spur development of a local cell therapy industry chain, including cold-chain logistics, clinical services and reagent supply. However, CAR-T commercialisation still faces challenges such as regulatory differences, production standardisation and payment systems, and New Zealand's limited market size means partners will need to rely on broader international markets to achieve returns. From an industry perspective, the global CAR-T field is dominated by giants such as Novartis and Gilead, and technology out-licensing by Chinese companies remains rare; this licence validates the recognition of Chinese innovative drugs in developed markets such as New Zealand and provides a reference path for more Chinese biotech companies to enter global markets via New Zealand.

New Zealand has a strong reputation in biomedical R&D and clinical trials but relatively weak industrialisation capacity, and whether such cooperation can sustainably create local high-value jobs and tax revenue depends on the depth of technology transfer and subsequent production arrangements. If a regional CAR-T production centre can be established in New Zealand in future, it would significantly enhance the country's competitiveness in cell therapy.

Keywords: CAR-T cell therapy, technology sublicence, China-New Zealand cooperation, Auckland, US$130 million, Wellington Zhaotai, BioOra, commercial licensing, Tang Chaoyang, biomedicine

Image for illustration purposes

Source: "Going Global" Navigator